Reducing Obesity Health Disparities in Hispanic Youth

Status Completed

Clinical Trial Summary

The proposed study will evaluate the efficacy of a family-based obesity prevention intervention in increasing physical activity and improving the quality of dietary intake among Hispanic Youth. Additional primary outcomes that will be examined include drug use and sexual risk behaviors. Secondary outcomes include examining the effects of family functioning and BMI. The knowledge expected to be gained in this study will have strong implications for prevention as well as contribute to the reduction of obesity-related health disparities seen in Hispanic youth.

Clinical Trial Description

This study's aims are: AIM 1: To examine the relative efficacy of Familias Unidas, extended to target obesity, in increasing physical activity and improving the quality of dietary intake among overweight Hispanic youth and AIM 2: To examine whether and to what extent family functioning partially mediates the effects of Familias Unidas on physical activity and quality of dietary intake. H1: Familias Unidas will be efficacious, compared to Community Practice, in increasing Hispanic youth's past moderate to vigorous physical activity over time. H2: Familias Unidas will be efficacious, compared to Community Practice, in improving Hispanic youth's past quality dietary intake (defined as decreases in dietary intakes of sugar-sweetened beverages, fast foods, and increases in dietary intakes of fresh fruits and vegetables) over time. H3: Familias Unidas' effects on youth's past day moderate to vigorous physical activity and youth's past quality dietary intake will be partially mediated by changes in family functioning over time. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03943628
Study type	Interventional
Source	University of Miami
Contact
Status	Completed
Phase	N/A
Start date	January 12, 2015
Completion date	December 27, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04507867` - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III	N/A
Terminated	`NCT03299881` - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss	N/A
Completed	`NCT02805478` - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting	`NCT02558920` - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed	`NCT03759743` - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject	N/A
Completed	`NCT03610958` - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.	N/A
Completed	`NCT03678766` - CHARGE: Controlling Hunger and ReGulating Eating	N/A
Completed	`NCT04430465` - Effects of Wholegrains on Children's Health (KORN)	N/A
Completed	`NCT04117802` - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Completed	`NCT05376865` - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers	N/A
Completed	`NCT03625427` - Effect of Palmitoleic Acid on C-reactive Protein	N/A
Active, not recruiting	`NCT03435445` - Online Platform for Healthy Weight Loss (POEmaS)	N/A
Enrolling by invitation	`NCT05576116` - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics	N/A
Recruiting	`NCT05249465` - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention	N/A
Active, not recruiting	`NCT06023095` - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities	Phase 1
Completed	`NCT03648892` - Brain Dopamine Function in Human Obesity	Early Phase 1
Recruiting	`NCT02887950` - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause	N/A
Completed	`NCT02829229` - Community-based Obesity Treatment in African American Women After Childbirth	N/A
Terminated	`NCT02796144` - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia	Phase 4
Terminated	`NCT02743598` - Liraglutide for HIV-associated Neurocognitive Disorder	Phase 4